| Identification | Back Directory | [Name]
PIK-293 | [CAS]
900185-01-5 | [Synonyms]
CS-539
PIK-293
PIK-293 PIK293
PIK-293 USP/EP/BP
PIK-293 (IC-87114)
PIK-293;PIK293;PIK 293
2-((4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one
2-[(4-aminopyrazolo[3,4-d]pyrimidin-1-yl)methyl]-5-methyl-3-(2-methylphenyl)quinazolin-4-one
2-[(4-Amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-5-methyl-3-(2-methylphenyl)-4(3H)-quinazolinone
4(3H)-Quinazolinone, 2-[(4-amino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl]-5-methyl-3-(2-methylphenyl)- | [Molecular Formula]
C22H19N7O | [MDL Number]
MFCD20272930 | [MOL File]
900185-01-5.mol | [Molecular Weight]
397.43 |
| Hazard Information | Back Directory | [Description]
PIK-293 is a cell-permeable, selective inhibitor of the phosphatidylinositol 3-kinase (PI3K) catalytic subunit p110δ (IC50s = 100, 25, 10, and 0.24 μM for p110 subunit isoforms α, β, γ, and δ, respectively). | [Uses]
PIK-293 is a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor and the parent compound of PIK-294 (P437705). Inhibition of PI3K’s shows to be a promising approach for cancer therapy. | [IC 50]
PI3Kδ: 0.24 μM (IC50); PI3Kβ: 10 μM (IC50); PI3Kγ: 25 μM (IC50); PI3Kα: 100 μM (IC50) | [References]
[1] ZACHARY A KNIGHT. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.[J]. Cell, 2006, 125 4: 733-747. DOI: 10.1016/j.cell.2006.03.035 |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|